Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra (SNi). As neurotrophic factors support the survival and enhance the function of dopaminergic neurons, gene therapy using neurotrophic factors has become the center of interest. Thus, we focused on hepatocyte growth factor (HGF) as a neurotrophic and angiogenic growth factor. At 7 days before injection of 6-hydroxydopamine into the SNi, stereotaxic transfection of human HGF or lacZ plasmid was performed into the unilateral striatum of rats. Expression of human HGF in the injected sites could be detected in rats transfected with HGF plasmid DNA, using immunohistochemical staining. Consistently, human immunoreactive HGF protein could be detected at least up to 12 days after transfection. Interestingly, PD rats transfected with lacZ demonstrated amphetamine-induced rotational asymmetry. However, transfection of HGF plasmid DNA resulted in significant inhibition of abnormal rotation up to 24 weeks in a dose-dependent manner. Over 90% of dopaminergic neurons were lost in PD rats transfected with lacZ, whereas over 70% survived in rats transfected with HGF, as assessed by immunohistochemical staining. Overall, the present study demonstrated that overexpression of HGF prevented neuronal death in a PD rat model, providing a potential novel therapy for PD.
Introduction
Gene therapy for the central nervous system is a promising approach to treat central nervous system diseases. Such novel therapy has been attempted clinically for glioblastoma, 1, 2 Parkinson's disease (PD) 3 and Canavan disease. 4 PD is a debilitating neurodegenerative condition characterized by progressive loss of dopaminergic neurons in the substantia nigra (SNi). Available therapies aim at replacing dopamine in the brain to restore motor function. 5, 6 However, it is essential to develop novel therapeutic interventions that block or slow down the ongoing degenerative process. A neuroprotective strategy, interfering with neuronal cell death or preventing neuronal dysfunction, may become the center of interest. 7, 8 Potential agents for neuroprotection include neurotrophic factors such as glial cell linederived neurotrophic factor (GDNF) and vascular endothelial growth factor (VEGF). In fact, various factors including GDNF and VEGF have been shown to increase dopaminergic neuronal survival and promote survival and axonal growth in animal models of PD. [9] [10] [11] In addition to those factors, we and others have reported a potential therapeutic strategy using hepatocyte growth factor (HGF). [12] [13] [14] [15] [16] [17] [18] [19] HGF acts as a neurotrophic and survival factor for embryonic motor neurons. 20 Moreover, sensory and sympathetic neurons and their precursors respond to HGF with increased differentiation, survival and axonal outgrowth. 20 The broad spectrum of HGF activity and its observed synergy with other neurotrophic factors suggest that the major role of HGF is to potentiate the response of developing neurons to specific signals. In addition, HGF is a well-known potent angiogenic growth factor in various models including a brain hypoperfusion model. Based on these unique properties of HGF, we examined the prevention of onset on PD by in vivo gene transfer of HGF in a rodent model. The present data demonstrated that gene transfer of HGF into the brain inhibited the loss of dopaminergic neurons in the SNi in a rat PD model.
Results
In this study, we employed direct injection of plasmid DNA rather than a viral vector system. Although viral vectors such as adenoviruses exhibit high transfection efficiency, there are serious safety problems such as immunogenicity, 21 delayed demyelination 22 and difficulty in preparation of a high titer of virus. 23 Therefore, we explored the possibility of gene therapy for PD using plasmid DNA. Initially, we demonstrated successful gene transfer of plasmid DNA by direct injection into the rat striatum, using immunohistochemical staining. Different from a viral vector, it is well known that transfection of plasmid DNA has low transfection efficiency, resulting in limited expression. Indeed, injection of plasmid DNA into the subarachnoid space did not show evidence of successful gene transfer (data not shown). Then, we directly injected human HGF plasmid DNA into the SNi, using a stereotactic technique. At 7 days, after transfection of naked human HGF plasmid, human HGF protein could be detected in the striatum as assessed by immunohistochemical staining (Figure 1 ). The area of expression was restricted to the injection site around the needle tract within 200-400 mm. In rats transfected with control vector, no human reactive HGF could be detected. Consistently, human reactive HGF protein could be detected in the transfected area by human HGF-specific enzyme-linked immunosorbent assay (ELISA) at least up to 12 days after transfection, whereas human HGF protein could not be detected in rats transfected with control vector (Figure 2 ).
Given the successful gene transfer, we further investigated whether HGF could reduce amphetamineinduced rotation in the PD model. For rats transfected with human HGF plasmid unilaterally, amphetamineinduced rotation was assessed from 2 to 24 weeks after 6-hydroxydopamine (6-OHDA) treatment. PD model rats without any treatment showed abnormal rotation of more than 10 full turns/min for 1 h. Similarly, rats transfected with lacZ plasmid DNA also showed abnormal rotational asymmetry, like the PD model (Po0.01, Figure 3 ), whereas normal (non-treated) rats did not rotate either clockwise or counterclockwise. Importantly, rats transfected with human HGF plasmid DNA showed only 2-3 rotations/min. The behavior of rats transfected with HGF plasmid DNA was similar to the pattern in normal rats ( Figure 3 ). Next, we examined the dosedependent effect of HGF to inhibit amphetamineinduced rotation from 2 to 8 weeks after 6-OHDA treatment. As shown in Figure 4 , transfection of HGF plasmid DNA resulted in significant inhibition of rotation in a dose-dependent manner (Po0.01).
To confirm the inhibitory effect of HGF on PD, we further studied the effect of HGF on neuronal death. In comparison to the number of dopaminergic neurons in non-treated rats (no injection of 6-OHDA), over 90% of dopaminergic neurons were lost in the PD model ( Figures 5 and 6 ). Transfection of LacZ plasmid DNA did not affect the number of dopaminergic neurons. In contrast, over 70% of dopaminergic neurons survived in rats transfected with human HGF plasmid DNA (Po0.01, Figures 5 and 6 ). The number of cells in the ventral tegmental area (VTA) was not changed. Furthermore, we carefully studied tissue damage in the striatum. As dysphagia, paresis or nausea due to severe damage in the striatum might cause body weight loss, we measured body weight after gene transfer in this study. Rats transfected with naked plasmid DNA showed no difference in body weight (data not shown). Similarly, histological staining also showed no histological change in the striatum. As shown in Figure 7 , GFAP staining as well as hematoxylin-eosin (HE) staining did not demonstrate gliosis or inflammatory change. In addition, no behavioral abnormality was observed.
Discussion
PD is a progressive neurodegenerative disorder that affects approximately 1 000 000 Americans. The cause of the disease remains unknown. The histopathological hallmarks are dopaminergic striatal insufficiency, secondary to a loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) and intracellular inclusions called Lewy bodies. As all currently available symptomatic treatment for PD has significant limitations, new therapeutic approaches are needed. Gene therapy might be ideal for delivering therapeutic molecules to site-specific regions in the central nervous system. Thus, researchers have tried to establish gene therapy such as usage of the tyrosine hydroxylase (TH) and GDNF as effective treatment. Especially, treatment with neurotorphic factors has become the center of interest, as a recent study demonstrated the clinical usefulness of recombinant GNDF in PD patients. 24 Gene therapy has the following advantages as compared to recombinant therapy: (1) It has the potential to maintain an optimally high and local concentration over time. It may be preferable to deliver a lower dose over a period of several days or more from an actively expressed transgene rather than a single or multiple doses of recombinant protein, to avoid side effects. (2) Regarding economics, which therapy would ultimately cost more to develop, implement and reimburse, particularly for those indications requiring multiple or even protracted treatment, needs to be considered.
In addition to GDNF, the present study demonstrated HGF to be a potential candidate for the treatment of PD. Both HGF and the c-Met/HGF receptor of membranespanning tyrosine kinase are expressed in various regions of the brain. 25 It is reported that sympathetic neurons of the superior cervical ganglion coexpress bioactive HGF and c-met both in vivo and in vitro.
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Exogenous HGF selectively promotes the growth of cultured sympathetic neurons; the magnitude of this growth effect is similar to that observed with exogenous nerve growth factor. 20 In addition, recent studies suggest that HGF prevents apoptosis in cerebellar granular neurons via the phosphatidylinositol-3 (PI3)-kinase/Akt pathway. 26 It is also reported that HGF cooperates with ciliary neurotrophic factor in promoting the survival and Gene therapy for Parkinson's disease H Koike et al growth of parasympathetic and proprioceptive neurons, and that within the same neurons, the effects of HGF on survival and growth are selectively dependent on which other signaling pathways are concurrently activated. 27 Given these unique properties, HGF is considered to be a novel neuroprotective agent. Indeed, administration of recombinant HGF as well as HGF gene therapy has been reported to protect hippocampal neurons from ischemiainduced delayed neuronal death. 28 In addition, a recent study provides a strong rationale for the potential clinical use of HGF for the treatment of motor neuron degenerative disease. 17 Based upon these studies, we examined the possibility that gene transfer of HGF into the striatum could have beneficial effects on dopaminergic neuronal death in a PD model in this study. As expected, overexpression of HGF in the striatum prevented the onset of PD in the rat model. Further studies are necessary for the progress toward human therapy, and could show therapeutic value of HGF for the treatment of PD.
One of the important points of the present study is the use of plasmid DNA in gene therapy, although numerous previous studies commonly used an adenovirus or adeno-associated virus. However, viral vectors have serious safety problems such as immunogenicity, 21 delayed demyelination 22 and difficulty in preparation of a high titer of virus. 23 As naked plasmid DNA is very safe and easy to handle as compared to viral vectors, intramuscular injection of naked plasmid DNA of angiogenic growth factors such as VEGF and HGF has been widely used clinically for the treatment of ischemic cardiovascular disease. [29] [30] [31] Some researchers have tried to apply direct injection of naked plasmid DNA into the brain; 32, 33 however, the transfection efficiency was quite low. 32 To overcome this problem, the injection site was localized using a streotactic technique with a high dosage. Consistent with the previous report, 33 we detected the exogenous protein of human HGF in the striatum. Interestingly, exogenous HGF was mainly expressed in reactive astrocytes, and that c-met was also expressed in the injection site. 33 Overall, the present study demonstrated that gene transfer of HGF protects dopaminergic neurons from the toxicity induced by 6-OHDA, resulting in prevention of the onset of PD. As no significant loss of body weight or histological change was observed throughout the experimental period, these data clearly demonstrate the clinical utility of a therapeutic strategy based upon plasmid DNA-mediated transfer. What is the clinical relevance of HGF gene transfer based upon plasmid DNA? First, it is possible to decrease the potential side effects and cost. Second, avoiding a viral gene transfer method such as an adenovirus may increase the safety of gene therapy and extend its application to a wide variety of targeted diseases. Third, further modification of delivery tools such as catheters may expand the utility of the present modification to transfection heading toward human gene therapy. Fourth, as expected, an in vivo study demonstrated no apparent toxicity in rats, although further studies on toxicity are necessary. In addition to its neurotrophic action, HGF is a potent angiogenic growth factor. Stimulation of local blood flow around the striatum, in addition to a neuroprotective action, might become a new therapeutic option to treat Parkinson's syndrome induced by common diseases in adults such as hypertension and diabetes.
Materials and methods

Plasmid DNA
To produce an HGF expression vector, human HGF cDNA (2.2 kb) 12, 17, 18 was inserted into a simple eukaryotic expression plasmid, pVAX1, that uses the cytomegalovirus promoter/enhancer (pVAX1/HGF). The vector used as a control was pcDNA3 expression vector plasmid, which was inserted into reporter enzyme b-galactosidase (pcDNA3/lacZ). Plasmid DNA was purified with a QIAGEN plasmid isolation kit (Hilden, Germany).
Transfection of HGF plasmid
A 6-week-old male Wistar rats weighing 120-140 g were housed in facilities with a standard 12 h light/dark cycle with free access to food and water. All surgical procedures were performed following an intraperitoneal Rats were placed in a stereotaxic instrument (Narishige, Tokyo, Japan). The skull was exposed and two holes were drilled above the left striatum. Naked human HGF plasmid DNA (10, 25, 50, 100 mg in 10 ml Tris and EDTA (TE)) and pcDNA3/LacZ plasmid DNA (100 mg in 10 ml TE) were transfected unilaterally into two sites in the left striatum using a Hamilton syringe. The sites of transfection were 1 mm anterior and posterior to the bregma, 2.5 and 3.5 mm lateral to the midline, and 4.5 and 5.5 mm below the surface of the brain, with the incisor bar fixed at 3.3 mm below the interaural line.
PD model induced by 6-OHDA lesion At 7 days after transfection of naked HGF plasmid, rats were unilaterally lesioned with 6-OHDA diluted to 16 mg in 4 ml 0.9% sterile saline containing 0.2 mg/ml ascorbic acid. 6-OHDA was injected unilaterally into the same side of the SNi before the transfection of HGF or pcDNA/lacZ. The sites of injection were 4.1 mm posterior to the bregma, 1.4 mm lateral to the midline and 7.2 mm below the surface of the brain. The PD model group underwent surgery, but no treatment into the striatum.
To assess the functional change, amphetamineinduced rotational asymmetry was tested from 2 to 24 weeks. Animals were subcutaneously injected with amphetamine (5 mg/kg) and placed in a rotation chamber for 60 min. Rotational behavior was recorded on a video tape system. Counterclockwise rotations were counted. The criterion for abnormal rotation was set at more than 10 full turns/min for 1 h.
Histlogical evaluation and HGF ELISA
At 1 week and 13 weeks after transfection of plasmid, rats were perfused transcardially with 0.9% NaCl solution followed by 200 ml 10% performaldehyde. The brain was dissected out, and post-fixed overnight in the same solution. Tissues were analyzed by immunohistochemical staining. The brain was sectioned at a thickness of 6 mm on a microtome, and blocking was performed in phosphate-buffered saline containing 1% bovine serum albumin. The following primary antibodies were used: anti-human HGF-b-chain (1:100; Institute of Immunology, Tokyo, Japan) and anti-TH (1:400; Chemicon, Temecula, CA, USA). These stains were developed by the avidin-biotin method (DAKO, Glostrup, Denmark, LSAB Kit) with diethylaminobenzidine as the chromogen. The number of TH-positive neurons in the SNi and VTA was counted under a light microscope (magnification, Â 200) in a blinded manner. GFAP (1:1000; mouse monoclonal; Sigma-Aldrich, St Louis, MO, USA) was examined as an indicator of gliosis, and HE staining was performed to examine inflammatory changes. Negative control sections from each animal received identical preparation for immunohistochemical staining, except that primary antibodies were omitted.
To document successful transfection of HGF vector into the striatum, we examined the production of human immunoreactive HGF at 3, 6, 9 and 12 days after transfection. The concentration of HGF in the striatum was determined by enzyme-immunoassay using antihuman HGF antibody. The antibody against human HGF reacts with only human HGF and not with rat HGF.
Statistical analysis
All values are expressed as mean7s.e.m. Analysis of variance with subsequent Duncan's test was used to determine the significance of differences in multiple comparisons. Differences with a P-value less than 0.05 were considered significant.
